🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications
Updated 04 Jul 2026 · HPRA open data

Octapharma (IP) — Licensed Medicines

15 medicines held by Octapharma (IP) on the Irish market, from the HPRA register of authorised products.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
← All medicines · 15 products held by Octapharma (IP)
MedicineActive substanceLicence holderStatus
Albunorm 20%, 200g/l, solution for infusion
PA2219/007/002
Human plasma protein not containing less than 96% human albumin Octapharma (IP) Marketed
Albunorm 5%, 50 g/l, solution for infusion
PA2219/007/001
Human plasma protein not containing less than 96% human albumin Octapharma (IP) Marketed
CUTAQUIG, 165 mg/ml, solution for injection
PA2219/001/001
Human normal immunoglobulin Octapharma (IP) Not marketed
FIBRYGA 2 g powder and solvent for solution for injection/infusion
PA2219/011/002
Human fibrinogen Octapharma (IP) Not marketed
FIBRYGA, 1 g, powder and solvent for solution for injection/infusion
PA2219/011/001
Human fibrinogen Octapharma (IP) Marketed
LG-octaplas, Powder and solvent for solution for infusion
PA2219/002/002
Human plasma protein Octapharma (IP)
LG-octaplas, solution for infusion
PA2219/002/001
Human plasma protein Octapharma (IP) Marketed
Octanate 1000 IU powder and solvent for solution for injection
PA2219/004/003
Human coagulation factor viii Octapharma (IP) Not marketed
Octanate 250 IU.Powder and solvent for solution for injection
PA2219/004/001
Human plasmafraktion (factor viii) Octapharma (IP) Not marketed
Octanate 500 IU powder and solvent for solution for injection
PA2219/004/002
Human coagulation factor viii Octapharma (IP) Not marketed
Octaplex 1000 IU coagulation factor IX per vial, powder and solvent for solution for infusionHuman Prothrombin Complex
PA2219/005/002
Human coagulation factor ix, Human coagulation factor ii, Human coagulation factor vii, Human coagulation factor x, Protein c Octapharma (IP) Marketed
Octaplex 500 IU coagulation factor IX per vial, powder and solvent for solution for infusionHuman Prothrombin Complex
PA2219/005/001
Human plasma coagulation factor ix, Human plasma coagulation factor ii, Human plasma coagulation factor vii, Human plasma coagulation factor x, Protein c Octapharma (IP) Marketed
Panzyga, 100 mg/ml solution for infusion
PA2219/010/001
Human normal immunoglobulin Octapharma (IP) Not marketed
Wilate, 1000 IU VWF/1000 IU FVIII, powder and solvent for solution for injection
PA2219/008/002
Human factor viii, Von willebrand factor human Octapharma (IP) Marketed
Wilate, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection
PA2219/008/001
Human factor viii, Von willebrand factor human Octapharma (IP) Marketed
Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 12 August 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.